Colgate-Palmolive (CL) is seen delivering Q2 results roughly in line with consensus, or with a slight beat, with organic revenue driven by ongoing international momentum and quarter-over-quarter improvement in North America, UBS said in a Wednesday note.
The company is scheduled to report Q2 financial results on July 31.
UBS analysts expect the company to meet its organic sales guidance range of 1% to 4%, even though growth is likely to modestly decline sequentially for the quarter.
Input costs are still marginally below the projected figures in Colgate-Palmolive's updated guidance, but the company is seen reiterating its outlook for low- to mid-single-digit EPS growth, the analysts said. Gross margin for 2026 is projected to drop slightly by 7 basis points from a year ago, while EPS is estimated at $3.80, in line with consensus and close to the midpoint of the company's implied guidance range, according to the note.
In the long-term, the analysts see an "attractive" catalyst path ahead for the stock, with growth in revenue and earnings anticipated to be improving into H2 and 2027.
The rating of UBS on the company's stock is buy with a price target of $106.
Price: $89.50, Change: $-2.13, Percent Change: -2.32%